Citations

Clear

1446 citation(s) found for "Howard, F".

A Multistate Survival Analysis for Patients with Follicular Lymphoma (FL) Using 13 First-Line Randomized Trials from FL Analysis of Surrogate Hypothesis (FLASH) Group
Çağlayan, Çağlar , Wall, Anna, Salles, Gilles , Herold, Michael , Sebban, Catherine, Hagenbeek, Anton, Marcus, Robert, Höchster, Howard S. , Rummel, Mathias , Foussard, Charles, Ghielmini, Michele, Nielsen, Tina, Foon, Kenneth A. , Flowers, Christopher R. , Salles, Gilles A , Dixon, Jesse G. , Hoster, Eva , Klapper, Wolfram , Morschhauser, Franck , Kimby, Eva , Vitolo, Umberto , Peterson, Bruce A., Gyan, Emmanuel , Ladetto, Marco , Shi, Qian

Mayo Clinic

Blood | November 14, 2019 | Volume: 134 | Issue: Supplement_1 | Pages: 2812-2812

10.1182/blood-2019-122328 Get It

Introduction: Most patients with newly diagnosed FL treated with rituximab (R) alone or R + chemotherapy will experience prolonged progression-free survival and overall survival (OS), but it remains unclear what factors have the greatest influence on FL-associated and other causes of death in this patient population. We utilized individual patient data from 13 first-line randomized clinical trials from the FLASH database to perform a comprehensive multistate survival analysis to examine and quantify the relationships between clinical characteristics, treatment response, and early, intermediate, and late FL outcomes. Methods: The multistate survival analysis model defined states for "Alive after beginning Induction Treatment (TX)", "Alive after beginning Maintenance TX", "Death due to FL", and "Death from Other Causes" (Figure 1). We used the Aalen-Johansen estimator, a generalization of the Kaplan-Meier estimator, to calculate the likelihood of being in each model state and estimate the course of FL over time. Making no assumptions on the probability distributions and capable of coping with censored observations, the Aalen-Johansen estimator is a convenient and reliable nonparametric estimator for clinical data. Results: Among 7,465 FL patients with median age 56 (range 18-90) years, 49.2% were female; 28.7% Stage I-III, 71.3% Stage IV, and FLIPI was 0-1 (20.0%), 2 (36.8%), ≥ 3 (43.2%). Following initiation of induction treatment, 2-, 5- and 10-year death rates were 1.7%, 3.8%, and 5.8% due to FL, and 0.7%, 2.1%, and 4.8% from other causes (Figure 2). Death rates at 2, 5, and 10 years due to FL and other causes for subgroups based on clinical characteristics and treatment response are shown in Table 1. Notably, patients > 70 years and patients with FLIPI ≥ 3 had worse outcomes and patients achieving CR at 18, 24, and 30 months experienced improved outcomes. Conclusion: This is the largest study using data from randomized trials to quantify the impact of clinical factors on early, intermediate and late mortality by cause of death. We demonstrated that age > 70 years and FLIPI ≥ 3 were linked to increased FL-associated death and response to TX distinguished patients with favorable and poor outcomes. Future analyses should quantify the impact of predictors on the rate/time of FL outcomes in multivariable models. Disclosures Salles: Roche, Janssen, Gilead, Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Amgen: Honoraria, Other: Educational events; BMS: Honoraria; Merck: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis, Servier, AbbVie, Karyopharm, Kite, MorphoSys: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events; Epizyme: Consultancy, Honoraria; Autolus: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Educational events. Hoster:Janssen: Research Funding; Roche Pharma AG: Other: Travel Support. Hiddemann:Bayer: Research Funding; Gilead: Consultancy, Honoraria; Vector Therapeutics: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Roche: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria. Herold:Roche: Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Gilead: Honoraria; Celgene: Honoraria. Morschhauser:Servier: Consultancy; Gilead: Consultancy; Janssen: Honoraria; Roche/Genentech: Consultancy; BMS: Honoraria; Celgene: Honoraria. Rummel:Roche Pharma AG: Honoraria, Research Funding; Celgene: Honoraria; Janssen: Honoraria; Sandoz: Honoraria. Kimby:AbbVie,: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Roche: Membership on an entity's Board of Directors or advisory committees; Jansen: Membership on an entity's Board of Directors or advisory committees; Gilead: Other: educational lectures. Vitolo:Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kite: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Juno Therapeutics: Membership on an entity's Board of Directors or advisory committees; F. Hoffmann-La Roche: Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Gyan:Pfizer: Honoraria. Ladetto:Celgene: Honoraria; Roche: Honoraria; Janssen: Honoraria; Abbvie: Honoraria; Acerta: Honoraria; Sandoz: Honoraria. Nielsen:F. Hoffmann-La Roche Ltd: Employment, Equity Ownership. Flowers:AstraZeneca: Consultancy; BeiGene: Consultancy, Research Funding; Eastern Cooperative Oncology Group: Research Funding; Burroughs Wellcome Fund: Research Funding; AbbVie: Consultancy, Research Funding; Optimum Rx: Consultancy; V Foundation: Research Funding; Pharmacyclics/Janssen: Consultancy, Research Funding; Bayer: Consultancy; Gilead: Consultancy, Research Funding; TG Therapeutics: Research Funding; Denovo Biopharma: Consultancy; Acerta: Research Funding; National Cancer Institute: Research Funding; Millenium/Takeda: Research Funding; Genentech, Inc./F. Hoffmann-La Roche Ltd: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; Spectrum: Consultancy;
Connect MM Registry as a national reference for United States multiple myeloma patients
Ailawadhi, Sikander , Narang, Mohit , Rifkin, Robert M. , Terebelo, Howard R. , Toomey, Kathleen, Durie, Brian G.M. , Gasparetto, Cristina, Wagner, Lynne I. , Omel, James, Kumar, Vivek , Yue, Lihua, Kitali, Amani, Agarwal, Amit , Abonour, Rafat , Investigators, on behalf of Connect MM Registry, Wagner, Lynne , Kumar, Vivek , Ailawadhi, Sikander , Jagannath, Sundar , Hardin, James W. , Gasparetto, Cristina , Investigators, on behalf of Connect MM Registry

Mayo Clinic

Cancer Medicine | November 8, 2019 | Volume: 9 | Issue: 1 | Pages: 35-42

10.1002/cam4.2656 | PMID 31701679 Get It

AbstractBackgroundThe Surveillance, Epidemiology, and End Results (SEER) database and National Cancer Database (NCDB) show improved overall survival (OS) in patients with multiple myeloma (MM) over the last 15 years. This analysis evaluated the validity of the largely community‐based Connect MM Registry as a national reference for MM.MethodsBaseline disease characteristics and survival in US newly diagnosed MM patients were examined using the Connect MM Registry as well as SEER and NCDB databases. Baseline characteristics predictive of longer survival in Connect MM were also identified.ResultsAs of February 2017, 3011 patients were enrolled in the Connect MM Registry; 2912 were treated. Median age at time of MM diagnosis and age range were numerically similar from 2010 to 2015 across all 3 registries; SEER had a higher representation of nonwhite racial groups than that in the other 2 registries. OS rates suggest proportionate improvement with year of diagnosis among the 3 registries. A Cox proportional hazards model suggests that younger age (<65 years) is associated with longer survival (vs ≥75; HR, 0.39; 95% confidence interval, 0.34‐0.46) in the Connect MM Registry. However, sex (HR, 0.91; P = .15) and race (black vs white; HR, 0.88; P = .21) were not associated with longer OS.ConclusionsData from the Connect MM Registry appear to be largely representative of national trends, comprehensive, and reliable representations of the national MM population. Baseline characteristics were comparable, and survival similarly improved over time among the 3 registries.ClinicalTrials.gov, identifierNCT01081028.
Adult day services and dementia caregivers’ daily affect: the role of distress response to behavioral and psychological symptoms of dementia
Bangerter, Lauren R. , Liu, Yin , Kim, Kyungmin , Zarit, Steven Howard , Kim, Kyungmin

Mayo Clinic

Aging & Mental Health | October 31, 2019 | Volume: 25 | Issue: 1 | Pages: 46-52

10.1080/13607863.2019.1681934 | PMID 31668091 Get It

NK cell defects in X-linked pigmentary reticulate disorder
Starokadomskyy, Petro , Wilton, Katelynn M. , Krzewski, Konrad , Lopez, Adam M., Sifuentes-Dominguez, Luis , Overlee, Brittany L., Ray, Ann , Gil‐Krzewska, Aleksandra, Peterson, Mary , Rohena, Luis , Grunebaum, Eyal , Grishin, Nick V. , Billadeau, Daniel D. , Chen, Qing , Kinch, Lisa N. , Zinn, Andrew R. , Burstein, Ezra

Mayo Clinic

JCI Insight | October 31, 2019 | Volume: 4 | Issue: 21 | Pages: No page available

10.1172/jci.insight.125688 | PMID 31672938 Get It

X-linked reticulate pigmentary disorder (XLPDR, Mendelian Inheritance in Man #301220) is a rare syndrome characterized by recurrent infections and sterile multiorgan inflammation. The syndrome is caused by an intronic mutation in POLA1, the gene encoding the catalytic subunit of DNA polymerase-α (Pol-α), which is responsible for Okazaki fragment synthesis during DNA replication. Reduced POLA1 expression in this condition triggers spontaneous type I interferon expression, which can be linked to the autoinflammatory manifestations of the disease. However, the history of recurrent infections in this syndrome is as yet unexplained. Here we report that patients with XLPDR have reduced NK cell cytotoxic activity and decreased numbers of NK cells, particularly differentiated, stage V, cells (CD3 – CD56 dim ). This phenotype is reminiscent of hypomorphic mutations in MCM4 , which encodes a component of the minichromosome maintenance (MCM) helicase complex that is functionally linked to Pol-α during the DNA replication process. We find that POLA1 deficiency leads to MCM4 depletion and that both can impair NK cell natural cytotoxicity and show that this is due to a defect in lytic granule polarization. Altogether, our study provides mechanistic connections between Pol-α and the MCM complex and demonstrates their relevance in NK cell function.
O4‐03‐01: FRONTOTEMPORAL LOBAR DEGENERATION RESEARCH IN NORTH AMERICA: PROGRESS IN THE ARTFL/LEFFTDS CONSORTIA
Heuer, Hilary W. , Boxer, Adam L. , Rosen, Howard J. , Forsberg, Leah K. , Brushaber, Danielle , Bordelon, Yvette , Coppola, Giovanni , Dickerson, Brad C., Dickinson, Susan, Faber, Kelley, Fields, Julie A. , Gavrilova, Ralitza H. , Ghoshal, Nupur , Graff‐Radford, Jonathan , Graff-Radford, N. R., Grant, Ian , Huey, Edward D. , Karydas, Anna M., Kaufer, Daniel , Kramer, Joel H. , Ljubenkov, Peter A. , Lucente, Diane , Lungu, Codrin , Mackenzie, Ian R. , McGinnis, Scott M., Mendez, Mario F. , Onyike, Chiadi U. , Pantelyat, Alex, Pearlman, Rodney , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Rogalskı, Emily , Shaw, Leslie M. , Sutherland, Margaret , Syrjanen, Jeremy A. , Tatton, Nadine , Taylor, Joanne, Weıntraub, Sandra , Consortia, ARTFL and LEFFTDS, Boeve, Bradley F. , Appleby, Brian S. , Brannelly, Patrick , Domoto‐Reilly, Kimiko , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Grossman, Murray , Hsiao, John , Hsiung, Ging‐Yuek Robin , Irwin, David J. , Kantarci, Kejal , Kerwin, Diana , Knopman, David S. , Kremers, Walter K. , Kukull, Walter A. , Litvan, Irene , Miller, Bruce L. , Roberson, Erik D. , Tartaglia, Maria Carmela , Toga, Arthur W. , Wong, Bonnie , Wszołek, Zbigniew K. , Consortia, ARTFL and LEFFTDS

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_23 | Pages: No page available

10.1016/j.jalz.2019.06.4752 Get It

O2‐05‐04: PLASMA PTAU181 LEVELS REFLECT [18F]AV1451 TAU PET UPTAKE ACROSS THE TAUOPATHY SPECTRUM
Thijssen, Elisabeth H. , Airey, David , Proctor, Nicholas K. , Chai, Xiyun, Sims, John R. , Bourakova, Viktoriya, Strom, Amelia , Karydas, Anna M., Wang, Ping , Heuer, Hilary W. , Kramer, Joel H. , Rosen, Howard J. , Jagust, William J. , Boxer, Adam L. , Rojas, Julio C. , Joie, Renaud La , Dage, Jeffrey L. , Airey, David C., Miller, Bruce L. , Boeve, Bradley F. , Rabinovici, Gil D.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_10 | Pages: No page available

10.1016/j.jalz.2019.06.4478 Get It

P2‐397: GYRIFICATION ABNORMALITIES IN PRESYMPTOMATIC C9ORF72 EXPANSION CARRIERS
Lee, Suzee E. , Battistella, Giovanni , Chu, Stephanie A. , Rosen, Howard J. , Karydas, Anna M., Coppola, Giovanni , Geschwind, Daniel H. , Rademakers, Rosa , Tempini, Maria Luisa Gorno , Caverzasi, Eduardo , Zanto, Theodore P. , Miller, Bruce L. , Seeley, William W.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_14 | Pages: No page available

10.1016/j.jalz.2019.06.2804 Get It